The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

NCT01617434 · Completed

Last updated 2026-05-28

This clinical trial tested the effects of the medication liraglutide compared to a placebo in adults with type 2 diabetes who were already taking basal insulin, with or without metformin, over a 26-week period.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 451 people

Who can join Ages 18–80 · all sexes

Timeline Started 2012-09 · est. completion 2013-10

Where 86 sites · Argentina, Canada, Finland, Germany, India, Mexico, Netherlands, Serbia, United States

What this study is testing ClinicalTrials.gov NCT01617434 ↗

Description as written by the study sponsor.

This trial is conducted in Asia, Europe and North and South America. The aim of the trial is to investigate the effect of liraglutide versus placebo when added to basal insulin analogues with or without metformin in subjects with type 2 diabetes.

Treatments tested

liraglutide Drug

Maximum 1.8 mg administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial basal insulin analogue regimen plus/minus metformin.
placebo Drug

Placebo administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial basal insulin analogue regimen plus/minus metformin.

Main thing measured	Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 26
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01617434 ↗